Kornimate/medical-research-clean huggingface dataset:
a clinical comparison of two soft contact lenses

Conditions: Myopia; Hyperopia

Summary: the study objective was to gather short-term clinical performance data for two soft contact lenses.

the aim of this subject-masked, non-randomized, controlled non-dispensing study was to evaluate the short-term clinical performance of a monthly sphere contact lens when compared to a daily disposable contact lens after 15 minutes of daily wear each.

Eligibility criteria:
inclusion criteria: * they are of legal age (18) and capacity to volunteer. * they understand their rights as a research subject and are willing and able to sign a statement of informed consent. * they are willing and able to follow the protocol. * they currently wear soft contact lenses, or have done so within the past two years. * they are expected to be able to be fitted with the study lenses within the power range available. exclusion criteria: * they have an ocular disorder which would normally contra-indicate contact lens wear. * they have a systemic disorder which would normally contra-indicate contact lens wear. * they are using any topical medication such as eye drops or ointment. * they are aphakic. * they have had corneal refractive surgery. * they have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus. * they are pregnant or lactating. * they have an eye or health condition including an immunosuppressive or infectious disease which would, in the opinion of the investigator, contraindicate contact lens wear or pose a risk to study personnel; or a history of anaphylaxis or severe allergic reaction. * they have taken part in any contact lens or care system clinical research within two weeks prior to starting this study.
effects of moderate physical activity on early symptoms of peripheral diabetic neuropathy in type-ii diabetes: a randomized clinical trial

Conditions: Peripheral Diabetic Neuropathy

Summary: this study determines the effects of moderate physical activity on early symptoms of peripheral diabetic neuropathy in type-ii diabetes. most of the literature shows the impact of physical activity to manage/controlling diabetes. some studies were conducted on animals to study the impact of physical activity on diabetic neuropathy and neurogenesis. there is no study on the impact of physical activity to manage early symptoms of peripheral diabetic neuropathy in patients with type-ii diabetes in humans. this study finds the impact of moderate physical activity to manage early symptoms of peripheral diabetic neuropathy in patients with type-ii diabetes in humans.


Eligibility criteria:
inclusion criteria: * patients with type-ii diabetes * diagnosed cases of peripheral diabetic neuropathy * peripheral diabetic neuropathy stage 1 \& 2 * numbness or reduced ability to feel pain or temperature changes. * tingling or burning sensation. * sharp pains or cramps. * increased sensitivity to touch * males and females * age: 35-65 * hba1c above 6.5 * mild activity level on ipaq-7 (\< 150min/per week) * berg balance scale score (\< 45) exclusion criteria: * cardiac issues * any neurological issue * lower limb deformity * acute injury * hip and knee oa * patients with walking difficulty * diabetic foot

Keywords: type 2 diabetes mellitus, moderate physical activity, hba1c, diabetic neuropathy
study of procoagulation markers in stroke patients

Conditions: Stroke; Hyperglycemia; Procoagulation Markers

Summary: the insights on selected procoagulation markers and outcomes in stroke trial (i-spot): response to insulin administration and blood glucose control proposal is designed to accompany the stroke hyperglycemia insulin network effort (shine) clinical trial, a phase iii multicenter, randomized, controlled trial planning to determine the efficacy and validate the safety of glycemic control in stroke patients. the shine trial will recruit 1,400 ais patients with type ii diabetes mellitus (t2dm) and hyperglycemia, each receiving 3 days of hyperglycemia control with intravenous (iv) insulin therapy or control therapy with subcutaneous (sq) insulin. the i-spot trial will recruit 315 shine patients. blood coagulation marker levels will be measured before and at 48 hours after the start of treatment. baseline and temporal changes in biomarkers levels will be compared between treatment groups. hypothesis: the decrease in levels of markers of blood coagulation will be greater in patients treated with iv insulin to reduce bg than in patients treated with sq insulin as the standard fashion. hypothesis: the decrease in levels of markers of blood coagulation will be greater in patients with than without favorable (shine) outcome (defined as the baseline stroke severity adjusted measure of functional ability at 90 days after ais). hypothesis: hyperglycemia control modulates the relationship between blood coagulation levels and functional outcome in t2dm patients after stroke. patients treated with iv insulin for hyperglycemia control with favorable (shine) outcome will have greater decreases in blood coagulation levels than either iv insulin-treated patients without favorable outcome or sq insulin-treated with or without favorable outcomes at 90 days after ais.


Eligibility criteria:
inclusion criteria: * enrolled in shine study * ability to give informed consent (self or lar) exclusion criteria: * current or planned use of full dose anticoagulation from baseline to the 48 hour sample collection * known moderate or severe hepatic insufficiency (as defined by inr\>1.5 if known or history of variceal bleeding or hepatic encephalopathy) * prior or concurrent thrombotic or hypercoagulable condition (antiphospholipid antibody syndrome; antithrombin iii, protein c or s deficiencies; congenital or inherited factor deficiencies; sickle cell disease)
evaluation using computed tomography angiography (cta) to investigate and detect atherosclerotic graft disease (elucidate)

Conditions: Arteriosclerosis of Coronary Artery Bypass Graft; Coronary Artery Disease

Summary: the purpose of clinical research is to look at the nature of disease and try to develop improved methods to diagnose and treat disease.the goal of this study is to evaluate the use of computed tomography (ct) scan of the heart in the diagnosis of disease in vein grafts after bypass surgery.

patients who have bypass surgery with using vein grafts from their legs (saphenous veins) have a very high risk of developing blockages in the grafts. it has been shown in previous studies that the progression of disease in vein grafts is very quick and can result in chest pain, heart attacks or death. in the past, evaluation of the grafts was possible with heart catheterization only. the technique of ct scan is currently considered an effective way to look at vein grafts as well as the arteries around the heart to identify blockages. certain blood proteins have been associated with rapid progression of vein graft blockages. our purpose is to not only to identify blockages at different stages after bypass surgery, but to investigate the causes of the rapid progression of the disease, including clinical history, risk factors and the blood proteins.

Eligibility criteria:
inclusion criteria: 1. ability to provide informed consent. 2. age equal to or greater than 18 years. 3. one(-/+60days), 3 (-/+60days), 5 (-/+60days), or 7 (-/+60days) years after coronary artery bypass graft surgery. exclusion criteria: 1. renal (kidney) insufficiency (creatinine greater than or equal to 1.6) or renal (kidney) failure requiring dialysis. 2. atrial fibrillation (type of heart rhythm) or other markedly irregular rhythm. 3. inability or refusal to provide informed consent. 4. pregnancy or unknown pregnancy status. 5. age less than 18 years. 6. clinical instability as deemed by the attending physician, including cardiogenic shock, hypotension (low blood pressure-systolic blood pressure less than 90 mmhg), refractory hypertension (high blood pressure) (systolic blood pressure greater than 180 mmhg), sustained ventricular or atrial arrhythmia (types of heart rhythm) requiring intravenous medications. 7. inability to tolerate beta-blockers, including those with chronic obstructive pulmonary disease (temporary narrowing of the tubes in the lungs) (or asthma requiring maintenance inhaled bronchodilators or steroids, complete heart block (chambers in the heart not beating in sync), second-degree atrioventricular block (chambers in the heart not beating in sync). 8. known contrast dye allergy.

Keywords: tomography coronary artery disease coronary artery bypass grafting vein graft
study to understand clinical characteristics, treatment pathway in chronic lymphocytic leukemia

Conditions: Chronic Lymphocytic Leukemia

Summary: a multicenter retrospective study to understand the clinical characteristics, treatment pathway and resource utilization for patients with chronic lymphocytic leukemia a retrospective, multi-centre, observational study to describe disease characteristics, treatment patterns, treatment-related outcomes, and resource utilization for chronic lymphocytic leukemia (cll) patients in multiple international regions

creek is a retrospective, observational, registry-based study including patients with an incidental diagnosis of cll and started treatment (1st line, 2nd line, or subsequent lines of treatment) within the period between 01 june 2016 and 12 months before data collection as identified from the patient records (from participating hospitals across the gcc states and the international region countries) with at least 12 months of follow-up, after starting on treatment. moreover, the study will include a pilot cohort in the gcc as an exploratory objective to describe the clinical and patient characteristics for the treatment-naive cll patient

Eligibility criteria:
inclusion criteria: * primary diagnosis of chronic lymphocytic leukemia (cll) * initiated cll treatment (including 1st line, 2nd line, or subsequent lines of treatment) within the period between 01 june 2016, and 12 months before data collection - for gcc pilot cohort patients: treatment-naive cll patients diagnosed between 01 june 2016, and 12 months before data collection. * available medical records at the participating site reflecting at least 12 months of follow-up after starting on treatment (except in the case of the participant death within one year following treatment initiation). * provision of informed consent by the patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver was granted), according to local regulations. * adult male or female ≥18 years old at the time of diagnosis or according to the age of majority as defined by local regulations). exclusion criteria: * failure to meet one or more of the inclusion criteria. * any diagnosis of b-cell malignancies other than cll. * current or prior use of "acalabrutinib" treatment. * currently/previously receiving treatment in an interventional clinical trial at the time of entry into this study for indications cll.

Keywords: chronic lymphocytic leukemia cll
pharmacokinetics, safety and tolerability of clascoterone cream 1% in healthy chinese adult subjects

Conditions: Acne Vulgaris

Summary: the primary objective of this study is to determine the pharmacokinetics (pk) of clascoterone cream, 1% after single dose and repeat dose topical administrations in healthy chinese adult subjects.


Eligibility criteria:
inclusion criteria: * chinese adult subjects, male or female; * 18-45 years of age (18 years old and 45 years old are inclusive, on the day of signing the written informed consent); * males should be ≥50.0 kg females should be ≥45.0 kg, respectively, and their body mass index \[bmi = weight (kg)/height2 (m2)\] should be within the range of 19.0 to 28.0 kg/m2 (including critical value); * female subjects of childbearing potential or male subjects whose partners are of childbearing potential should agree and be able to use effective contraception from the time of signing the written informed consent to within 3 months after the last dosing (see appendix 2 for details); * subjects should be able to communicate well with the investigator and complete the study as per the protocol; subjects should be fully informed about the study and sign a written informed consent voluntarily. exclusion criteria: * subject has a previous history of chronic or serious disease; * subject who has undergone major surgical procedure or procedure affecting drug absorption, distribution, metabolism, or excretion within 6 months prior to screening, or plans to undergo surgery during the study; * subject has a history of drug abuse and drug dependence; * subject who has received any medication prior to screening; * subject has previous allergies or has allergic symptoms; * subject has skin damages; * subject who has consumed alcohol regularly; * subject has positive testing result of drug abuse and narcotics screening ; * subject who has consumed excessive of strong tea, coffee, or caffeine-containing beverages; * subject who has been addicted to smoking; * subject who has intake of grapefruit-rich beverages or foods; * subject who has participated in a clinical study with another drug or device and has used the drug or device prior to screening * subject who has donated blood or bled heavily , or received a blood transfusion or used blood products; or who plans to donate blood or blood components; * subject has abnormal physical examination result at screening, or abnormal result of vital signs, or abnormal ecg findings; * subject has abnormal and clinically significant results of clinical laboratory tests; * subject who is a pregnant or lactation woman or has positive pregnancy test result; * subject who is unable to follow a uniform diet; * subject who has difficulty in collecting blood, has a history of needle and blood fainting or cannot tolerate venipuncture;
a study to evaluate the effect of vx-661 in combination with ivacaftor on chest imaging endpoints in subjects with cystic fibrosis, homozygous for the f508del cftr mutation

Conditions: Cystic Fibrosis

Summary: the primary purpose of study is to evaluate the treatment effect of tezacaftor in combination with ivacaftor (tez/iva) on chest imaging endpoints using low-dose computed tomography (ldct) at week 72, and to evaluate the safety of tez/iva through week 72.


Eligibility criteria:
inclusion criteria: * homozygous for the f508del cftr mutation * confirmed diagnosis of cf * percent predicted forced expiratory volume (ppfev1) ≥70% of predicted normal for age, sex, and height during screening. * stable cf disease as judged by the investigator exclusion criteria: * history of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. * an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 28 days before day 1 (first dose of study drug) * pregnant or nursing females. * sexually active subjects of reproductive potential who are not willing to follow the contraception requirements. * any contraindication to undergoing chest imaging, as per the site's institutional guidelines
stellate ganglion block in cerebral palsy

Conditions: Cerebral Palsy

Summary: the goal of this clinical trial is to test the efficacy of stellate ganglion block in children with cerebral palsy and dysphagia. the main question it aims to answer are: • can stellate ganglion block improve the dysphagia of children with cerebral palsy? participants were randomly divided into two groups, all provided with routine therapy. based on this, the experimental group was given stellate ganglion block. the video fluoroscopic swallowing study was done to test the swallowing function before and after the study.

cerebral palsy is a common non-progressive clinical condition characterized by motor disorders and abnormal postures, which significantly impact the quality of life of affected children. swallowing dysfunction is a common complication in children with cerebral palsy , affecting their daily eating and communication skills, and hindering their nutritional development and social interaction. stellate ganglion block has shown certain efficacy in improving swallowing function in children with cerebral palsy. however, there is limited research on the effects of stellate ganglion block treatment on swallowing dysfunction in children with cerebral palsy. therefore, this study aims to explore this topic and provide scientific evidence for its clinical application. the goal of this clinical trial is to test the efficacy of stellate ganglion block in children with cerebral palsy and dysphagia. the main question it aims to answer are: • can stellate ganglion block improve the dysphagia of children with cerebral palsy? participants were randomly divided into two groups, all provided with routine therapy. based on this, the experimental group was given stellate ganglion block. the video fluoroscopic swallowing study was done to test the swallowing function before and after the study.

Eligibility criteria:
inclusion criteria: * meeting the diagnostic criteria of cerebral palsy formulated by the 13th national conference on pediatric cerebral palsy rehabilitation; * age between 4 to 7 years; * diagnosed as dysphagia confirmed by dysphagia disorder survey or pediatric esophagoscopy; exclusion criteria: * with dysphagia caused by other diseases or factors; * with progressive neurological disease or degenerative neurological disease; * with severe heart disease, liver or kidney dysfunction, hematological disorders, or other acute and severe symptoms; * with abnormalities in the oral cavity, pharynx, esophagus, or other parts of the digestive tract; * with poor compliance.
gastric restriction using the endosurgical operating system

Conditions: Obesity

Summary: the primary objective is to collect data on the use of the endosurgical operating system (eos) for gastric tissue approximation during primary gastric restrictive procedures.


Eligibility criteria:
inclusion criteria: * patient has met diabetic lab testing and all pre-procedural qualifications as delineated below. * patient is \>/= 20 yrs. of age and \</= 60 yrs. of age * patient has a bmi of \>/=30 and \< 40 * patient has history of obesity for \>/= 2 yrs. * patient has had not significant weight change (\<5% of total body weight) in last 6 months. * patient is a reasonable candidate for general anesthesia * patient agrees not to have any additional weight loss surgery or liposuction for 2 yrs. following procedure. exclusion criteria: * patient is not able and willing to return for all follow-up evaluations, tests and nutritional counseling. * patient is not able to provide written informed consent * patient has history or present use of insulin or insulin derivatives for treatment of diabetes. * patient has diabetes secondary to a specific disease. * patient has history of inflammatory disease of gi tract * patient has diabetic retinopathy * patient has chronic pancreatic disease * patient ahs active peptic ulcer * patient has portal hypertension * patient has esophageal varices * patient has significant esophageal disease * patient has a history of any significant abdominal surgery * patient has a history of any bariatric or gerd surgical procedures * patient has a hiatal hernia \> 2cm. * patient has esophageal stricture or other anatomy and/or condition that could preclude passage of endolumenal instruments * patient is of childbearing age and not practicing effective birth control method, pregnant or lactating. * patient has had a mi or cva in last year, or has unstable cardiovascular disease. * patient has cancer or life expectancy of \< 2 yrs. * patient currently uses or has used over the counter or prescription weight loss drugs in last month or intends to use during follow-up registry period. * patient has quit smoking within last 6 months or plans to quit smoking in the next year. * patient has a history of durg or alcohol abuse * patient has uncontrolled depression, psychosis, or eating disorder. * patient is non-ambulatory or has significant impairment of mobility. * patient has known hormonal or genetic cause for obesity. * patient is participating in another registry and/or study that could adversely affect this registry.

Keywords: gastric restriction
comparative effects of clamshells and frog pump exercises

Conditions: Iliotibial Band Syndrome

Summary: iliotibial band syndrome is where a tendon called iliotibial band gets irritated or swollen from rubbing against hip or knee when it gets too tensed. iliotibial band (itb) syndrome (itbs) is the most common cause of lateral knee pain among athletes who are involved in sports that require continuous running or repetitive knee flexion and extension. the incidence ranges from 1.6% to 12% in runners. the aim of the study is to compare the effects of clamshells and frog pump exercises on gluteus medius strengthening and lower extremity function in runners with iliotibial band syndrome.

this study will be a randomized clinical trial and will be conducted in pakistan sports board lahore. non-probability convenient sampling will be used to collect the data. sample size of 32 subjects with age group between 18-30 years (males) will be taken. data will be collected from the runners with tight itb, by using tools lefs, hos-ss, and hand held dynamometer. an informed consent will be taken. a total of 26 subjects will be selected by following inclusion and exclusion criteria and will equally divided in to two groups by random number generator table. both the groups will continue the conventional training with group a will receive clamshell exercise, and group b will receive frog pump exercise in their respective training programs. outcome measures will be measured at baseline and after 2 weeks. data analysis will be done by spss version 25.

Eligibility criteria:
inclusion criteria: * • age (18-30yrs) * gender (males) * positive ober's test * positive noble's compression test * suffering pain from past 3 months * running approximately 5km/week exclusion criteria: * • osteoporosis * previous knee trauma/surgery * patellofemoral joint pain * popliteus tendinitis * lateral meniscal injure

Keywords: gluteus medius pain iliotibial band syndrome strength